Skip to main content

Safety Pharmacology

At the interface between biology, pathophysiology, pharmacology and toxicology, safety pharmacology is a full-fledged discipline. It is also a key issue for all drug developers of the healthcare industry: unacceptable safety remains the most important reason for failure in preclinical and phase I studies (safety is also responsible for 30% of the phase II trial failures).

Over the past 40 years, ERBC has become a leader in the field, conducting annually more than 200 non GLP or GLP-compliant safety studies.

In partnership with world-class scientists of academia and industry, ERBC is also fully committed to the development of safety biomarkers and advanced methodologies that allow industrials to better predict the risk of rare lethal events induced by new therapies and improve safety margin calculation, reducing the risk of subsequent failure in clinical.

Equipment and infrastructure

  • Safety pharmacology suite
  • Imaging unit (X-ray & fluoroscopy)
  • Patch clamp unit
  • Telemetry system
  • Surgical rooms
  • Data center
  • Analytics lab
  • Animal facilities (dedicated facilities for each specie)
our expertise by

Therapeutic areas

Cardiology

Neurology

Pneumology

Oncology

Immuno-oncology

Allergy

Dermatology

Gastro-enterology

Analgesia/inflammation

Endocrinology

Haematology

Nephrology

A comprehensive range of preclinical models for short and long-term toxicology studies

Our animal models

John joe

Mouse

John joe

Rat

John joe

Dog

John joe

Rabbit

John joe

Marmoset

John joe

Ferret

John joe

Cynomolgus Monkeys

John joe

Guinea Pig

John joe

Cat

John joe

Hamster

John joe

MiniPig

A wide range of services that span the entire drug discovery and development continuum and can be tailored to specific research conditions

Our Services

NEED TO CREATE YOUR

UNIQUE PROJECT

Each project is managed by a study director, relying on a multi-disciplinary team of experts.